Functional polymorphisms of the receptor for the advanced glycation end product promoter gene in inflammatory bowel disease: a case-control study
Language English Country Italy Media print-electronic
Document type Journal Article
PubMed
31175506
DOI
10.1007/s10238-019-00562-x
PII: 10.1007/s10238-019-00562-x
Knihovny.cz E-resources
- Keywords
- Gene polymorphisms, Inflammatory bowel disease, RAGE,
- MeSH
- Adult MeSH
- Gene Frequency MeSH
- Genetic Predisposition to Disease * MeSH
- Genotype MeSH
- Genotyping Techniques MeSH
- Inflammatory Bowel Diseases genetics MeSH
- Polymorphism, Single Nucleotide * MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Polymorphism, Restriction Fragment Length MeSH
- Prevalence MeSH
- Promoter Regions, Genetic * MeSH
- Receptor for Advanced Glycation End Products genetics MeSH
- Case-Control Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- AGER protein, human MeSH Browser
- Receptor for Advanced Glycation End Products MeSH
The receptor for the advanced glycation end products (RAGE) is a multiligand transmembrane receptor involved in chronic inflammation whose specific polymorphisms of the promoter gene were found to increase its transcriptional activity. We investigated the association of both allelic and genotypic -374T/A and -429T/C polymorphisms with inflammatory bowel disease. The STREGA guidelines were applied for planning and reporting. We enrolled 133 patients with Crohn's disease (CD), 149 with ulcerative colitis (UC), and 128 blood donors. Genomic DNA was extracted from peripheral blood leukocytes collected from each patient and control. RAGE polymorphisms were analyzed by PCR-restriction fragment length polymorphism assay. The Hardy-Weinberg equilibrium was first assessed, and then, the Kruskal-Wallis test and the Fisher exact test were used for etiologic group comparisons. Distribution of patients' characteristics across genotypes was evaluated by the Fisher exact test, while that across alleles was analyzed with a probit model. A 2-sided value of p < 0.05 was considered significant. Following the evidence of the Hardy-Weinberg equilibrium, we found a higher prevalence of the allele A of the -374T/A haplotype in UC (p = 0.043), and of the allele C of the -429T/C haplotype in CD (p < 0.001) with respect to the other groups. Moreover, the homozygous AA genotype of the -374T/A polymorphism resulted associated with late onset of CD, while its TT genotype with early onset (p = 0.049). The allele C of the 429T/C haplotype was associated with early onset of UC (p = 0.03), while a higher frequency of the heterozygous TC haplotype was found in those with pancolitis (p = 0.026). The differing distribution of these polymorphisms in healthy donors and CD/UC patients suggests a role in the development and outcome of these pathological conditions.
Department of Internal Medicine Brothers of Mercy Hospital Polni 3 63900 Brno Czech Republic
Faculty of Health and Social Work Trnava University Trnava Slovakia
Gastroenterology and Digestive Endoscopy Unit Legnano Hospital ASST Ovest Milanese Legnano Italy
See more in PubMed
Biochim Biophys Acta. 2000 Dec 20;1498(2-3):99-111 PubMed
Diabetes. 2001 Jun;50(6):1505-11 PubMed
J Clin Invest. 2001 Oct;108(7):949-55 PubMed
Gastroenterology. 1976 Mar;70(3):439-44 PubMed
Gut. 2003 Jun;52(6):847-53 PubMed
J Mol Med (Berl). 2005 Nov;83(11):876-86 PubMed
Gut. 2006 Jun;55(6):749-53 PubMed
Am J Pathol. 2006 Oct;169(4):1223-37 PubMed
Clin Chem Lab Med. 2007;45(10):1268-72 PubMed
Arch Med Res. 2008 Apr;39(3):320-5 PubMed
PLoS Med. 2009 Feb 3;6(2):e22 PubMed
J Leukoc Biol. 2009 Sep;86(3):633-43 PubMed
J Mol Neurosci. 2009 Nov;39(3):360-5 PubMed
Annu Rev Immunol. 2010;28:367-88 PubMed
Gut. 2011 Nov;60(11):1580-8 PubMed
Am J Physiol Gastrointest Liver Physiol. 2011 May;300(5):G823-32 PubMed
Gut. 2011 May;60(5):571-607 PubMed
Am J Gastroenterol. 2011 Nov;106(11):2029-40 PubMed
Inflamm Bowel Dis. 2012 Apr;18(4):782-92 PubMed
J Crohns Colitis. 2011 Oct;5(5):402-6 PubMed
Lupus. 2012 Aug;21(9):959-68 PubMed
Clin Dev Immunol. 2012;2012:823085 PubMed
PLoS One. 2012;7(7):e41913 PubMed
Nature. 2012 Nov 1;491(7422):119-24 PubMed
Gut. 2015 Aug;64(8):1227-35 PubMed
BMJ. 1989 Jan 14;298(6666):82-6 PubMed
Nat Genet. 2015 Sep;47(9):979-986 PubMed
Immunol Lett. 2016 Feb;170:88-94 PubMed
J Crohns Colitis. 2016 Mar;10(3):239-54 PubMed
Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):13-27 PubMed
Lancet. 2017 Apr 29;389(10080):1741-1755 PubMed
Lancet. 2017 Apr 29;389(10080):1756-1770 PubMed
Trends Pharmacol Sci. 2017 Feb;38(2):127-142 PubMed
Curr Med Chem. 2018 Sep 03;:null PubMed
Mucosal Immunol. 2019 Mar;12(2):468-478 PubMed
Genomics. 1994 Sep 15;23(2):408-19 PubMed
Scand J Gastroenterol. 1996 Mar;31(3):260-6 PubMed
Dan Med Bull. 1997 Jun;44(3):287-302 PubMed
Diabetes. 1998 Jul;47(7):1155-7 PubMed